iFR is the global gold standard among resting indices, with a Class IA recommendation in the ACC/AHA/SCAI and ESC Guidelines.1,3 This is backed by clinical evidence and patient outcomes showing reduced costs, procedural time and patient discomfort.2 iFR also provides advanced guidance with iFR pullback and co-registration for PCI planning throughout the entire case. Learn more about the latest iFR patient studies and view the latest 5-year outcomes update.
Unseen focal lesions cause residual ischemia. The DEFINE PCI study used iFR pullback to understand the rate and causes of residual ischemia in 500 patients undergoing contemporary PCI. Early results find that residual ischemia is common, and causes are treatable.3,4
Understand residual ischemia as mapped by iFR pullback after successful angiographic PCI and its implications for procedural improvement.
DEFINE Flair and iFR Swedeheart are two prospective randomized controlled studies published in the prestigious New England Journal of Medicine and combined represent the largest physiology clinical dataset with more than 4500 patients. Learn more DEFINE FLAIR, iFR Swedeheart.
* p-values are for non-inferiority of an iFR-guided strategy versus an FFR-guided strategy with respect to 1-year MACE rates; pre-specified non-inferiority margins were 3.4% and 3.2% in DEFINE FLAIR and iFR Swedeheart, respectively.
** MACE rates at 5-years: 21.5% iFR vs. 19.9% FFR (HR 1.09; 95% CI: 0.90, 1.33)
Reduced costs per patient
DEFINE FLAIR and iFR Swedeheart found that on average, compared to FFR, iFR resulted in:
Less procedural time
DEFINE FLAIR found that an iFR-guided strategy resulted in:
Improved care
The two trials further established that an iFR-guided strategy enables a faster procedure while almost completely eliminating severe patient symptoms compared to an FFR-guided strategy.